Unique ID issued by UMIN | UMIN000006022 |
---|---|
Receipt number | R000007112 |
Scientific Title | Induction chemoradiotherapy followed by surgery without mediastinal lymphnode disection in stage IIIA(bulkyN2)/IIIB non-small cell lung cancer |
Date of disclosure of the study information | 2011/07/31 |
Last modified on | 2015/01/22 11:59:00 |
Induction chemoradiotherapy followed by surgery without mediastinal lymphnode disection in stage IIIA(bulkyN2)/IIIB non-small cell lung cancer
Induction chemoradiotherapy followed by surgery without mediastinal lymphnode disection in stage IIIA(bulkyN2)/IIIB non-small cell lung cancer
Induction chemoradiotherapy followed by surgery without mediastinal lymphnode disection in stage IIIA(bulkyN2)/IIIB non-small cell lung cancer
Induction chemoradiotherapy followed by surgery without mediastinal lymphnode disection in stage IIIA(bulkyN2)/IIIB non-small cell lung cancer
Japan |
non-small cell lung cancer
Pneumology | Chest surgery |
Malignancy
NO
Feasibility of induction chemoradiotherapy followed by surgery without mediastinal lymphnode disection in stage IIIA(bulkyN2) /IIIB non-small cell lung cancer
Safety,Efficacy
Feasibility
OS, PFS, efficacy of induction chemoradiotherapy, severe adverse effects of surgery.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
Induction chemoradiotherapy followed by surgery without mediastinal lymphnode disection in stage IIIA(bulkyN2) /IIIB non-small cell lung cancer
15 | years-old | <= |
80 | years-old | > |
Male and Female
1)Histologically or cytologically confirmed non-small cell lung cancer.
2)Stage IIIA(bulkyN2)/IIIB lung cancer.
3)No prior treatment
4)Resectable primary tumor.
5)More than 16 years old-less than 75 years old.
6)PS0-1
7)At least one or more measurable lesion by RECIST.
8)Adequate organ function.
9)Written Informed Consent.
1)Active co-morbidities.
2)Interstitial lung disease.
3)Active infection.
4)Severe heart disease.
5)Contralateral hilar lymphnode metastasis
6)Neurological disorder.
7)Active double cancer.
8)Psychotic disorder.
9)Histology of grave allergic reaction.
10)Pregnancy, breast feeding and supected pregnancy.
11)Patients whose participation in the trial is judged to be inappropriate.
45
1st name | |
Middle name | |
Last name | Toshiki Hirata |
Iseikai Hospital
Respiratory Disease Center
6-2-25 Sugawara, Higashiyodogawa-ku, Osaka City, 533-0022, Japan.
06-6326-1121
1st name | |
Middle name | |
Last name |
Iseikai Hospital
Respiratory Disease Center
06-6326-1121
Iseikai Hospital
Iseikai Hospital
Self funding
NO
2011 | Year | 07 | Month | 31 | Day |
Unpublished
Terminated
2011 | Year | 06 | Month | 20 | Day |
2011 | Year | 08 | Month | 01 | Day |
2014 | Year | 08 | Month | 01 | Day |
2014 | Year | 08 | Month | 01 | Day |
2014 | Year | 08 | Month | 01 | Day |
2014 | Year | 08 | Month | 01 | Day |
2011 | Year | 07 | Month | 22 | Day |
2015 | Year | 01 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007112